How will German early benefit assessments change in the future?
Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in
Category: News and updates
How does the G-BA pick the appropriate comparator?
Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude
IQWiG sees problems in how PROs are included in registrational studies
This week, we are having a brief look at two brief reports on PROs recently published by the IQWiG. We’ll cover: As
Which endpoints are important to the G-BA and IQWiG?
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about:
Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?
This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early